Brief: Shanghai Junshi Biosciences Says Unit Passed FDA On-Site Inspection
22/10/2025 16:21
Oct 22 (Reuters) - Shanghai Junshi Biosciences 688180.SS: UNIT PASSING FDA ON-SITE INSPECTION Further company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab